Encephalitis clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
open to eligible people ages 18 years and up
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Orange, California and other locations
Our lead scientists for Encephalitis research studies include Xiao-Tang Kong, MD.